BACKGROUND: Atazanavir, an azadipeptide protease inhibitor (PI) with once daily dosing, a lack of insulin resistance, lipid increase, and gastrointestinal toxicities, is approved in combination with other antiretrovirals for the treatment of patients infected with HIV. Unboosted atazanavir is also used in highly active antiretroviral therapy (HAART) naive patients. METHODS: The study prospectively followed up an established cohort of patients who received atazanavir, and for whom one year of follow up data were available. RESULTS: It was found that use of atazanavir in intent to treat and on treatment analyses, maintained and led to virological suppression and increases in CD4 count in both PI naive and experienced patients. Virological failure occurred in 7% of patients and the main toxicity was hyperbilirubinaemia, which led to treatment withdrawal in 2%. Its efficacy and safety profile was similar to that seen in previous randomised studies investigating its use. CONCLUSIONS: These data should provide reassurance for clinicians wishing to introduce a new antiretroviral into an established cohort.
BACKGROUND:Atazanavir, an azadipeptide protease inhibitor (PI) with once daily dosing, a lack of insulin resistance, lipid increase, and gastrointestinal toxicities, is approved in combination with other antiretrovirals for the treatment of patients infected with HIV. Unboosted atazanavir is also used in highly active antiretroviral therapy (HAART) naive patients. METHODS: The study prospectively followed up an established cohort of patients who received atazanavir, and for whom one year of follow up data were available. RESULTS: It was found that use of atazanavir in intent to treat and on treatment analyses, maintained and led to virological suppression and increases in CD4 count in both PI naive and experienced patients. Virological failure occurred in 7% of patients and the main toxicity was hyperbilirubinaemia, which led to treatment withdrawal in 2%. Its efficacy and safety profile was similar to that seen in previous randomised studies investigating its use. CONCLUSIONS: These data should provide reassurance for clinicians wishing to introduce a new antiretroviral into an established cohort.
Authors: A Ammassari; R Murri; P Pezzotti; M P Trotta; L Ravasio; P De Longis; S Lo Caputo; P Narciso; S Pauluzzi; G Carosi; S Nappa; P Piano; C M Izzo; M Lichtner; G Rezza; A Monforte; G Ippolito; M d'Arminio Moroni; A W Wu; A Antinori Journal: J Acquir Immune Defic Syndr Date: 2001-12-15 Impact factor: 3.731
Authors: Robert L Murphy; Ian Sanne; Pedro Cahn; Praphan Phanuphak; Lisa Percival; Thomas Kelleher; Michael Giordano Journal: AIDS Date: 2003-12-05 Impact factor: 4.177
Authors: Patrick G Yeni; Scott M Hammer; Martin S Hirsch; Michael S Saag; Mauro Schechter; Charles C J Carpenter; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Esteban Martínez; Juan A Arnaiz; Daniel Podzamczer; David Dalmau; Esteban Ribera; Pere Domingo; Hernando Knobel; Melcior Riera; Enric Pedrol; Lluis Force; Josep M Llibre; Ferran Segura; Cristóbal Richart; Cristina Cortés; Manuel Javaloyas; Miquel Aranda; Ana Cruceta; Elisa de Lazzari; José M Gatell Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245
Authors: Robin Wood; Praphan Phanuphak; Pedro Cahn; Vadim Pokrovskiy; Willy Rozenbaum; Giuseppe Pantaleo; Michael Sension; Robert Murphy; Marco Mancini; Thomas Kelleher; Michael Giordano Journal: J Acquir Immune Defic Syndr Date: 2004-06-01 Impact factor: 3.731
Authors: Aoife G Cotter; Aisling Brown; Gerard Sheehan; John Lambert; Caroline A Sabin; Patrick Wg Mallon Journal: AIDS Res Ther Date: 2013-05-16 Impact factor: 2.250